Introduction of Global R&D Project Deal of New Drugs

CHEN Ling,QIN Tianlei,ZOU Xu,HUANG Wenlong
DOI: https://doi.org/10.3969/j.issn.1673-7210.2010.33.004
2010-01-01
Abstract:Deals speak volumes about company sentiment and the overall health of the pharmaceutical industry.The rank-ing of the pharmaceutical industry's most large dealmakers,hot therapy areas centered-deals,and the deal profile of differ-ent study stages to the first three quarters of 2009 were reviewed in this paper.In the meantime,the pharmaceutical status quo of the RD climate was pointing out:pursuing the hybrid model to maximize the profit;small-molecule drugs was re-gaining popularity with increase in small-molecule-focused deals;and the divestiture of the non-nuclear assets.
What problem does this paper attempt to address?